Odyssey Health Inc

For the period ended Jan 31, 2024. Filed Mar 22, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jan 31, 2024 · Filed Mar 22, 2024

ODYYStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

	Three Months Ended January 31,		Six Months Ended January 31,
	2024	2023	2024	2023
In-process research and development expense	$–	$170,000	$–	$170,000
Research and development expense	42,765	3,889	65,766	358,104
Stock-based compensation	677,391	659,777	1,000,188	1,439,667
General and administrative expense	437,274	652,826	938,716	1,596,525
Loss from operations	(1,157,430)	(1,486,492)	(2,004,670)	(3,564,296)
Gain on sale of asset	15,900,687	–	16,400,687	–
Investment revaluation	(1,332,980)	–	(1,332,980)	–
Interest expense	(141,601)	(194,191)	(332,462)	(265,493)
Other income, net	8,890	8,955	8,956	8,481
Net income (loss)	13,277,566	(1,671,728)	12,739,531	(3,821,308)
Deemed dividend	(63,455)	–	(63,455)	–
Net income (loss) attributable to common stockholders	$13,214,111	$(1,671,728)	$12,676,076	$(3,821,308)
Basic net income (loss) per share	$0.14	$(0.02)	$0.14	$(0.05)
Diluted net income (loss) per share	$0.12	$(0.02)	$0.12	$(0.05)
Shares used for basic net income (loss) per share	91,975,356	81,784,549	89,879,237	81,616,937
Shares used for diluted net income (loss) per share	114,056,382	81,784,549	112,043,228	81,616,937

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.